Speaker Profile: Christopher C. Gallen, MD, PhD

After receiving his M.D. and Ph.D. (Biochemistry) degrees and completing a medical internship at the Emory University School of Medicine, Dr. Gallen went on to complete Psychiatry residency training at Stanford and Neurology residency training at the University of California, San Diego. He then joined the Neuropharmacology Department of The Scripps Research where he developed an international reputation in brain functional imaging, published the first definitive demonstration of human cerebral plasticity, and was as a scientific support to the successful IPO and secondary offerings of Biomagnetic Technology Inc (BTi). Dr. Gallen next took on responsibilities rising to Senior Director of Medical and Scientific at Quintiles directing several successful registration programs. Dr. Gallen then started the Premier Research Worldwide CRO, led its IPO, grew it into a successful trans-Atlantic CRO and conducted trials in a wide variety of therapeutic areas and approaches. Dr. Gallen subsequently moved to work in big pharma with responsibilities as Vice President of Medical Development at Pharmacia including three major roles, Head of Global CNS Medical Development, Head of Clinical Operations managing the “internal CRO” for conduct of all clinical trials in all Therapeutic Areas in the Western Hemisphere and eventually, after helping lead a successful re-engineering, as Kalamazoo R&D Site Head CNS and ID, Dr. Gallen subsequently became Vice President and Chief of Operations for Clinical Research and Development at Wyeth in charge of a range of global clinical development functions. In this role Dr. Gallen partnered with Accenture to help create the Alliance for Clinical Data Excellence (ACE) outsourcing of Wyeth Clinical Data Management to Accenture and to drove the successful re-engineering of Wyeth to the top quintile of clinical research performance. Dr. Gallen subsequently became President and CEO of Neuromed, a Philadelphia and Vancouver-based biopharma company developing products to manage and treat complications of pain, epilepsy and hypertension.

Christopher Gallen will be hosting the panel discussion "Leading Through Change: Innovation and Future of the BioPharmaceutical Industry," Wednesday, April 29, 2009 at 8:30 AM.